Provided by Tiger Trade Technology Pte. Ltd.

Corvus Pharmaceuticals

14.46
+0.13000.91%
Post-market: 14.800.3400+2.35%19:36 EDT
Volume:473.79K
Turnover:6.88M
Market Cap:1.21B
PE:-23.13
High:14.76
Open:14.52
Low:14.38
Close:14.33
52wk High:26.95
52wk Low:5.22
Shares:83.77M
Float Shares:74.12M
Volume Ratio:0.67
T/O Rate:0.64%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.6252
EPS(LYR):-0.5320
ROE:-35.43%
ROA:-21.66%
PB:5.38
PE(LYR):-27.18

Loading ...

Top Executive Makes Bold Insider Move on Corvus Pharmaceuticals Stock

TIPRANKS
·
May 21

Corvus CEO Richard Miller reports trust buy of USD 83,112 common shares

Reuters
·
May 21

Corvus Pharmaceuticals presents at Jefferies Global Healthcare Conference

Reuters
·
May 21

Corvus Pharmaceuticals Down Over 11%, On Track for Largest Percent Decrease Since March 2025 -- Data Talk

Dow Jones
·
May 14

Goldman Sachs Sticks to Its Buy Rating for Corvus Pharmaceuticals (CRVS)

TIPRANKS
·
May 12

Corvus Loss, Shelf Offering and Soquelitinib Progress Might Change The Case For Investing In CRVS

Simply Wall St.
·
May 12

Analysts Offer Insights on Healthcare Companies: Apogee Therapeutics (APGE), Intellia Therapeutics (NTLA) and Corvus Pharmaceuticals (CRVS)

TIPRANKS
·
May 11

Stock Track | Corvus Pharmaceuticals Plummets 5.76% Intraday on Widening Q1 Loss and Rising R&D Expenses

Stock Track
·
May 08

Corvus Q1 FY26 results: net loss widens to $13.7 million; R&D expense rises to $11.2 million

Reuters
·
May 08

Corvus Pharma Q1 EPS $(0.15), Inline

Benzinga Earnings
·
May 08

Corvus Pharmaceuticals Provides Business Update and Reports First Quarter 2026 Financial Results

GlobeNewswire
·
May 08

A Look At Corvus Pharmaceuticals (CRVS) Valuation After Adding Immunology Leader Dr. Andrew C. Chan To Its Board

Simply Wall St.
·
May 03

Earning Preview: Corvus Pharmaceuticals revenue is expected to be flat, and institutional views are broadly bullish

Earnings Agent
·
May 01

Corvus Pharmaceuticals director Andrew C. Chan files initial beneficial ownership statement

Reuters
·
Apr 28

Corvus Pharmaceuticals announces upcoming annual shareholder meeting

Reuters
·
Apr 25

Press Release: Corvus Pharmaceuticals Appoints Andrew C. Chan, M.D., Ph.D., to Board of Directors

Dow Jones
·
Apr 23

Corvus publishes update to financial calendar

Reuters
·
Apr 21

Corvus Pharmaceuticals to Host Investor and Analyst Meeting on May 14, 2026 to Highlight Soquelitinib Data Being Presented at the Society for Investigative Dermatology (SID) Annual Meeting

GlobeNewswire
·
Apr 21

Goldman Sachs Initiates Corvus Pharmaceuticals at Buy With $40 Price Target

MT Newswires Live
·
Apr 17

Stock Track | Corvus Pharmaceuticals Plummets 10.61% Intraday on Dilution Fears from Expanded $200 Million ATM Facility

Stock Track
·
Mar 19